Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice

EBioMedicine(2023)10.1016/j.ebiom.2023.104713Source: DataRank Database

The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice is a research paper published in EBioMedicine (2023). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 3.86)OA: goldTopics (30)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Liping Zhang ORCID,Ahmed Elsherbini ORCID,Simone M. Crivelli ORCID,Priyanka Tripathi ORCID,C. Harper

Live enrichment

PubMed:37480622 OpenAlex:https://openalex.org/W4385157098

National Institutes of Health

Grant: R01AG064234

National Institutes of Health

Grant: R21AG078601

National Institutes of Health

Grant: RF1AG078338

U.S. Department of Veterans Affairs

Grant: I01BX003643

FWCI

3.86

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.thelancet.com/article/S2352396423002785/pdf

publisherhttp://www.thelancet.com/article/S2352396423002785/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2352396423002785?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352396423002785?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ebiom.2023.104713

Fields of Study

Sphingolipid Metabolism and SignalingNeuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

MeSH Terms

Sphingosine-1-Phosphate ReceptorsNeuroinflammatory DiseasesAlzheimer DiseaseAnimalsAnti-Inflammatory AgentsDisease Models, AnimalMice, TransgenicThiazolesCytokinesAmyloid beta-PeptidesMicrogliaToll-Like Receptor 4Mice

Keywords

MicrogliaNeuroinflammationTLR4PharmacologyS1PR1AstrogliosisMedicineBiologyImmunologyEndocrinologyReceptorInternal medicineInflammationCentral nervous system

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Inhibition of acid sphingomyelinase reduces reactive astrocyte secretion of mitotoxic extracellular vesicles and improves Alzheimer’s disease pathology in the 5xFAD mouse

10.6084/m9.figshare.26611727.v1figshare

Additional file 1 of Inhibition of acid sphingomyelinase reduces reactive astrocyte secretion of mitotoxic extracellular vesicles and improves Alzheimer’s disease pathology in the 5xFAD mouse

10.6084/m9.figshare.26611727figshare